212Pb-DOTAMTATE Appears Safe, Effective in PRRT-Naïve Patients With SSTR+ GEP-NETs
212Pb-DOTAMTATE demonstrated activity and was considered well tolerated in patients with unresectable or metastatic SSTR+ GEP-NETs who had not received prior PRRT.
Related Articles
Sorafenib Plus Valproic Acid and Sildenafil Proves Active in High-Grade Glioma
The combination of sorafenib tosylate, valproic acid, and sildenafil demonstrated activity in a phase 2 trial of patients with high-grade glioma.
Advances in small cell lung cancer classification
Recent research in classifying subtypes of small cell lung cancer is bringing renewed hope for treatment advances. To learn more, we spoke with Carl Gay,…
ASTRO issues update to clinical guideline on radiation therapy for rectal cancer
Press release to promote updated ASTRO clinical guideline for radiation therapy to treat patients with locally advanced rectal cancer
Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC
Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.
The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high‐quality lung cancer screening
This component of the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) strategic plan examines the impediments to successful adoption, dissemination, and implementation of…
State Cancer Profiles
State Cancer Profiles is an interactive map engine produced in collaboration between the National Cancer Institute and Centers for Disease Control and Prevention. It was…
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities
Nature Reviews Cancer – Androgen receptor (AR) signalling plays an important role in several cancers beyond prostate cancer. This Review highlights the context-dependent functions of…
Abstracts
Learn more about and submit your abstract to the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.
Revumenib receives FDA approval for adult and pediatric patients aged ≥1 year with R/R acute leukemia and a KMT2A translocation
On November 15, 2024, the FDA approved revumenib for the treatment of adult and pediatric patients aged ≥1 year with R/R acute leukemia with a…
Banking on mRNA: engineered platelets
In this issue of Blood, Strong et al1 demonstrate the compatibility of mRNA lipid nanoparticle (LNP) transfection to genetically engineer platelet componen
